Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
SAN DIEGO, Jan. 19, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE MKT:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, will host a conference call on Monday, February 8, 2016 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal third-quarter 2016 financial results. In advance of the call on February 8, 2016, Organovo will issue its fiscal third-quarter 2016 earnings press release, which will be available at http://www.organovo.com. To participate in the teleconference, callers can dial the following numbers:
1-888-317-6003 (toll-free, U.S. callers only)
1-412-317-6061 (from outside the U.S.)
Conference Call ID: 5006379
To help ensure the conference call begins in a timely manner, please dial in five minutes prior to the scheduled start time. The conference call will also be simultaneously webcast at http://www.organovo.com.
For those unable to participate in the live call, a replay of the call will be available toll-free until February 15, 2016 at 1-877-344-7529 (U.S. callers only) or at 1-412-317-0088 (callers outside the U.S.). The passcode for the replay is: 5006379. An archived replay of the webcast will also be available at http://www.organovo.com.
About Organovo Holdings Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company recently launched its initial product of the planned exVive3DTM portfolio offering, the exVive3D Human Liver Tissue for use in toxicology and other preclinical drug testing. Additional products are in development, with the anticipated release of the exVive3D Human Kidney Tissue scheduled for the third quarter of calendar year 2016. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous other media outlets. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.
Investor Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 [email protected] Press Contact: Jessica Yingling Little Dog Communications +1 (858) 480-2411 [email protected]
